Search Results 591-600 of 15130 for TNF

  1. Clinical trials - Oncology (Medical)

    The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per ...

  2. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    This is a combination Phase I and Phase II study, with an aim to evaluate the combination of GSK525762 and fulvestrant in women with advanced or metastatic ER+ ...

  3. A Study to Evaluate Regional Radiotherapy in Biomarker Low-Risk Node Positive Breast Cancer - Mayo Clinic

    The purpose of this study is to compare the effects on low-risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no ...

  4. Neurofibromatosis type 1 - Doctors and departments - Mayo Clinic

    Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...

  5. Arteriosclerosis / atherosclerosis - Doctors and departments - Mayo Clinic

    Departments and specialties. Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, ...

  6. Brian A. Neff, M.D. - Doctors and Medical Staff - Mayo Clinic

    Neurotology/skull base; Chronic otitis media, middle ear reconstruction; Cholesteatoma; Otosclerosis, acoustic neuroma, cochlear implants; BAHA ...

  7. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer - Mayo Clinic

    For the dose that meets the safety criterion in Stage 1, at least 1 response in melanoma subjects and 2 responses in TNBC subjects amongst the 12 subjects ...

  8. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

    ... tumor necrosis factor agents) with the exception of corticosteroid treatment ≤ 10 mg/day prednisone or equivalent within 2 weeks prior to first dose of ...

  9. Publications - David P. Martin, M.D., Ph.D. - Mayo Clinic

    Valencia Morales DJ, Laporta ML, Zec S, Yu K, Bancos I, Martin DP, Martin McGrew YN, Weingarten TN, Hanson AC, Sun J, Schroeder DR, Sprung J. Hemodynamics in ...

  10. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Mayo Clinic

    FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures. The study has two arms: a “longitudinal arm” ...